Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

Inclusion Criteria: * Adult patients aged 18-75 * Proven or suspected respiratory sepsis aetiology * Acute respiratory failure currently requiring invasive mechanical ventilation for not more than 48 hours duration * Horowitz Index for Lung Function (Pa02/Fi02 Ratio) ≤200mmHg or ≤26.6kPa * Sequential organ failure assessment score (SOFA) ≥4 and ≤ 14 * Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law). Exclusion Criteria: * Expected duration of invasive mechanical ventilation less than 48 hours * The use of other non-routine extracorporeal sepsis treatments such as very high flux renal replacement therapy (\>60ml/kg/h total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc). * Presence of severe multiple organ failure at the point of enrolment as evidenced by: * Severe refractory vasoplegic failure * Norepinephrine dose \> 0.60 μg/kg/min * Use of epinephrine * Concomitant cardiogenic shock, clinically suspected or CI\<2.2 if measured * Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan * Coagulopathy as defined by platelet count \<50 * Calculated Plasma Volume greater than 5000ml as determined by an estimation of total blood volume (according to Nadler's formula, incorporating height, weight and sex) multiplied by (1- Haematocrit). A total blood volume calculator is available at https://www.omnicalculator.com/health/blood-volume * Long term oxygen therapy or home oxygen use * Liver cirrhosis (histologically proven or clinically suspected) * Active bleeding * Citrate intolerance if citrate is required for therapeutic apheresis * Heparin allergy if heparin is required for therapeutic apheresis * Metastatic disease with life expectancy of \<12 months and ECOG score of at least 2 * Haematological malignancy if not in remission * Solid organ transplant and concomitant use of immunosuppression * Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D) * Prior use of cardiopulmonary resuscitation (CPR) in index admission * Requirement for extracorporeal membrane oxygenation (ECMO) * Patient expected to die within 48 hours of admission to ICU * Known allergy to components of NucleoCapture * Current Participation in another interventional clinical trial * Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)